鳞状细胞癌抗原在宫颈癌同步放化疗后结局预测与治疗决策中的作用
本文综述鳞状细胞癌抗原(SCC Ag)在局部晚期宫颈癌同步放化疗(CCRT)中的临床价值。疗前SCC Ag升高与广泛肿瘤及较差生存相关,可辅助手术决策以避免双重治疗并发症;CCRT期间SCC Ag下降速率可预测肿瘤反应,疗后未正常化可预测复发(特异性高于70%),并可用于随访中早期发现复发,敏感性高且成本效益好。
要点
- 疗前SCC Ag升高与广泛肿瘤及CCRT后较差生存相关。
- SCC Ag下降速率可预测CCRT后肿瘤反应。
- 疗后SCC Ag未正常化预测复发特异性高于70%。
核心结论
- SCC Ag可用于宫颈癌CCRT患者的结局预测、治疗决策及随访复发监测。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 疗前SCC Ag升高与广泛肿瘤及接受根治性CCRT的宫颈癌患者较差生存相关。
- CCRT期间SCC Ag下降速率可预测治疗后肿瘤反应。
- 疗后SCC Ag未正常化预测肿瘤复发的特异性高于70%。
- SCC Ag在CCRT后随访中早期发现肿瘤复发具有高敏感性和良好成本效益。
关键数值与推荐
- 疗后SCC Ag未正常化预测复发的特异性高于70%,应考虑辅助治疗。
- SCC Ag升高与放疗抵抗相关。
临床怎么用
- 疗前SCC Ag可辅助 physicians 决定手术以避免双重治疗并发症。
- CCRT期间监测SCC Ag下降速率以预测肿瘤反应。
- 疗后SCC Ag未正常化者考虑辅助治疗。
- 随访中利用SCC Ag早期发现复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At present, the standard treatment approach for locally advanced cervical cancer is concurrent chemoradiotherapy (CCRT). An elevated pretreatment squamous cell carcinoma antigen (SCC Ag) level is associated with extensive tumors and poor survival for patients with cervical cancer treated with definitive CCRT. SCC Ag levels can be used to help physicians make decisions regarding surgery, avoiding the complications of double treatment modalities. Elevated SCC Ag is associated with radiotherapy resistance, and the rate of SCC Ag reduction during CCRT can predict tumor response after treatment. Moreover, the failure of SCC Ag levels to normalize posttreatment can predict tumor relapse, with a specificity higher than 70%, and adjuvant therapies should be considered for these patients. SCC Ag also plays an important role in the early detection of tumor relapse in patients with cervical cancer during follow-up after CCRT, with high sensitivity and good cost-effectiveness.
引用
- Fu J, Wang W, Wang Y, et al. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019. PMID: 31416463. doi:10.1186/s13014-019-1355-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。